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Background: Ovarian cancer, an inflammation-associated cancer, is the fifth leading cause of cancer deaths in
women. The malignancy produces a large amount of tumor necrosis factor (TNF) which promotes a
proinflammatory tumor microenvironment. In addition, the epidermal growth factor receptor (EGFR) is frequently
overexpressed in high-grade ovarian cancer, which likely aggravates cancer progression. Since ovarian cancer
progression is closely associated with chemokine networks driven by inflammation or EGFR activation, we
investigated the chemokine signatures elicited by EGF and TNF in ovarian cancer cells to determine their individual
profiles and if there was in fact some kind of synergy between their actions on the chemokine network.
Methods: We used a PCR array for the chemokine network to examine the signature of chemokines and their
receptors elicited by EGF and TNF in four ovarian cancer cell lines (OVCAR-3, SKOV-3, CaOV-3 and TOV-21G).
Results: The chemokine network revealed that ovarian cancer cells commonly expressed high levels of
proinflammatory chemokines such as CCL20, CXCL1-3 and CXCL8 in response to EGF or TNF. However, the
responsiveness to EGF or TNF displayed a cell line specific pattern. Although OVCAR-3 and SKOV-3 cells were
responsive to either EGF or TNF, their TNF responsiveness was dominant. On the other hand, CaOV-3 and TOV-21G
cells were responsive to EGF but less to TNF, probably due to the high levels of non-canonical nuclear factor
(NF)-κB components such as IKKα and p52 in these cell lines compared to OVCAR-3 and SKOV-3 cells. Among
chemokine receptors, only CXCR5 was responsive to EGF or TNF in CaOV-3 cells. Finally, CCL20 and CXCL8
responded synergistically in response to EGF and TNF in OVCAR-3 and SKOV-3 cells.
Conclusion: Our results indicate that CCL20, CXCL1-3 and CXCL8 are the primary chemokines induced by EGF or
TNF and are elicited in these ovarian cancer cells via NF-κB, Akt and Erk signaling pathways. Of interest, there was a
syngergistic response in terms of CCL20 and CXCL8 levels, when OVCAR-3 and SKOV-3 cells were exposed to EGF
plus TNF. Targeting these proinflammatory chemokines may be a promising therapeutic strategy for ovarian cancer
with abundant TNF and EGFR activation patterns.
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Inflammation-associated ovarian cancer is the fifth lead-
ing cause of cancer deaths among women. Chronic in-
fection and inflammation are considered to be among
the most important epigenetic and environmental fac-
tors contributing to tumorigenesis and cancer progres-
sion [1-3]. Ovarian cancer cells highly express highly
tumor necrosis factor (TNF), indicating the importance
of TNF as a regulator of the proinflammatory tumor* Correspondence: dson@mmc.edu
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reproduction in any medium, provided the ormicroenvironment in this malignancy [3-6]. Thus block-
age of the TNF network using neutralizing antibodies or
siRNA reduces the ovarian cancer burden [7]. Particularly,
TNF regulates chemokine networks through the nuclear
factor-κB (NF-κB) signaling pathway. Chemokines are
critical mediators of cell migration into and out of the
tumor microenvironment and represent major players in
cancer progression and metastasis [8,9]. In our previous
study, inflammatory agents including bacterial endotoxin
lipopolysaccharide (LPS) and proinflammatory cytokines
interleukin-1 (IL-1) and TNF, induced CXCL1-3 and
CXCL8 in ovarian cancer cells by involving NF-κB signaling. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pression of TNF expressed higher levels of CXCR4 than
cells with a low TNF expression level [11].
The ErbB/EGFR family of receptors consists of four
structurally-related type 1 transmembrane tyrosine kin-
ase receptors: EGFR (ErbB1, HER1), ErbB2 (HER2, neu),
ErbB3 (HER3) and ErbB4 (HER4) [12,13]. Activation of
ErbB/EGFR tyrosine kinase receptors recruits multiple
signaling pathways which play important roles in cell
proliferation, survival, adhesion, motility, invasion and
angiogenesis [12,13]. EGFR is frequently overexpressed
in high-grade malignant ovarian cancer [14,15]. Because
of the multiple signaling processes originating from
EGFR activation, EGFR overexpression has been corre-
lated with a poor prognosis and a decreased therapeutic
responsiveness in patients with ovarian cancer [12]. The
phosphatidylinositol 3-kinase (PI3K) which acts as a
main downstream signaling pathway for EGF is fre-
quently activated, leading to increased cell survival. Fur-
thermore, EGFR activation may also involve chemokine
networks through its downstream signaling pathways.
CXCL1 and CXCL8, in particular, have been identified
as secreted proteins regulated by EGF and the PI3K
pathway in ovarian cancer cell lines [16]. In addition,
EGF enhances the expression of CXCR4 as well as mi-
gration of ovarian cancer cells [17].
These limited reports indicate that ovarian cancer pro-
gression is closely associated with chemokine networks
driven by inflammation or EGFR activation. Therefore it
is important to identify which chemokines are primarily
regulated by TNF and EGF to order to devise a thera-
peutic strategy based on the chemokine signature seen
in this malignancy. Thus the present study was designed
to assess the characteristics of the chemokine profiles
elicited by EGF and TNF, and determine if they induce
any synergistic effects with respect to key chemokines in
ovarian cancer cell lines. For the purposes of this study,




Recombinant human TNF and EGF were obtained
from R&D Systems (Minneapolis, MN, USA). Antibodies
were purchased from the following vendors: ErbB iso-
form, p65 and β-actin from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and NF-κB family, IKK isoforms,
IκB, Akt, Erk and their phosphorylated forms from Cell
Signaling Technology (Beverly, MA, USA). The PCR
array for customized human chemokines, specific PCR
primers for CCL2, CCL20, CXCL1-3, CXCL8, CXCL16,
CXCR5, β-actin, and SYBR® Green Master Mix came
from SABiosciences/Qiagen (Frederick, MD, USA).
Chemiluminescent detection kits were from GE Healthcare(Piscataway, NJ, USA). Penicillin G/streptomycin was
purchased from Sigma (St. Louis, MO, USA) and
Lipofectamine 2000 and all liquid culture media were
acquired from Invitrogen (Grand Island, NY, USA). BAY-
11-7082, LY294002 and PD98059 were purchased from
Cayman Chemical (Ann Arbor, MI, USA). The Luciferase
Reporter Assay System was obtained from Promega
(Madison, WI, USA).
Cell lines, cell culture, and media additions
The human ovarian cancer cell lines OVCAR-3, SKOV-3,
CaOV-3 and TOV-21G were purchased from the American
Type Culture Collection (ATTC, Manassas, VA, USA).
Human cancer cells (approximately 5 × 104 cells/ml) were
cultured at 37°C in a water-saturated atmosphere of 95%
air and 5% CO2 in 24- or 6-well plates with RPMI medium
containing 10% fetal bovine serum (FBS) with penicillin
(100 U/ml)/streptomycin (100 U/ml). After an overnight
culture to allow cellular attachment to the plates, the
medium was removed and fresh medium without FBS
was added to remove the effects of serum, per se. Where
indicated, vehicle (phosphate-buffered saline, PBS), 10 ng/ml
EGF, 10 ng/ml TNF, or a combination of EGF and TNF
was added, and incubations continued for the indicated
time periods.
PCR array and real-time PCR
After isolating total RNA and eliminating genomic DNA,
reverse transcription reactions were performed at 42°C for
15 min followed by 94°C for 5 min. According to manufac-
turers’ instructions, a real-time PCR was performed using a
Bio-Rad CFX96 (Hercules, CA, USA) under the following
two-step cycling program: 1 cycle at 95°C for 10 min, 40
cycles at 95°C for 15 sec and at 60°C for 1 min. Data ana-
lysis was performed based on a Web-Based PCR Array
Data Analysis protocol (http://pcrdataanalysis.sabiosciences.
com/pcr/arrayanalysis.php) provided by SABiosciences
(Qiagen).
Western blots
Cell lysates were prepared, resolved on SDS-polyacrylamide
gels and transferred to nitrocellulose membranes according
to established procedures [13]. Blocking of nonspecific
proteins was performed by incubation of the mem-
branes with 5% nonfat dry milk in Tris buffered saline
Tween-20 (TBST, pH 8.0) for 2 h at room temperature.
Blots were incubated with primary antibodies at 1:1,000
dilution in blocking solution overnight at 4°C. The mem-
branes were washed 3 times with TBST for 10 min and
incubated for 1 h with horseradish peroxidase-conjugated
secondary antibody at 1:2,500 in 5% milk/TBST. The mem-
branes were then rinsed 3 times with TBST for 10 min and
the bands were visualized by enhanced chemiluminescence.
After membrane stripping for 10 min with methanol
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serve as an internal loading control.
Construction of the CCL20 and CXCL8 promoter-luciferase
genes
DNA fragments of the human CCL20 and CXCL8 genes
were generated by PCR using genomic DNA isolated
from OVCAR-3 cells. Primer sets were designed as fol-
lows: 5′-GGA GTT CTG GAA TGT TCC TG -3′ for a
sense containing a XhoI site and 5′-TAC CCA GTT
CTT TGG GAG TG-3′ for an antisense containing a
HindIII site for the CCL20 promoter (−376/+20) and 5′-
CAC CTG CCA CTC TAG TAC TA-3′ for a sense
containing a XhoI site and 5′-CCT TAT GGA GTG
CTC CGG TG-3′ for an antisense site containing a
HindIII site for the CXCL8 promoter (−322/+10). The
PCR reaction was performed for 35 cycles at 94°C for 30
sec, 58°C for 30 sec and 74°C for 1 min with a final ex-
tension at 74°C for 10 min. The amplified CCL20 and
CXCL8 DNA fragments were digested with XhoI and
Hind III and the fragments were purified according to
manufacturer‘s instructions (Gel Extraction System,
Qiagen, Valencia, CA). The purified CCL20 and CXCL8
promoter genes were subcloned into the XhoI and
HindIII sites of the pGL4.12-basic vector (Promega,
Madison, WI, USA). The constructs of the CCL20 and
CXCL8 promoter-luciferase genes were confirmed by
DNA sequencing analysis.
Transient transfection and luciferase assays
Human ovarian cancer cells at approximately 50%
confluency in 24-well plates were washed once with
fresh media without additives and were transiently
transfected for 24 h at 37°C using Lipofectamine
solution. Transfected cells were treated as outlined in
Results and incubated for 6 h. After rinsing cells with
ice-cold PBS and adding lysis buffer (Promega,
Madison, WI), cell lysates were used for determination
of luciferase activity using a microplate luminometer.
Luciferase activity, expressed as relative light units,
was normalized to measured protein levels.
Statistical analysis
Data were analyzed by the paired Student’s t-test and one-
way analysis of variance (ANOVA) as appropriate. If a stat-
istical significance (P ≤ 0.05) was determined by ANOVA,
the data were further analyzed by Tukey’s pairwise com-
parisons to detect specific differences between treatments.
Results
EGF- or TNF-responsive chemokine signature in ovarian
cancer cells
We selected ovarian cancer cell lines OVCAR-3, SKOV-
3, CaOV-3 and TOV-21G to determine PCR arrayscontaining genes that encode human chemokines and
chemokine receptors after the addition of EGF or TNF.
The present study used the nomenclature of chemokines
approved by the IUIS/WHO Subcommittee on Chemo-
kine Nomenclature (2002). The mRNA levels of a panel
of 43 chemokines and 19 chemokine receptors were
evaluated for each of the 4 cell lines. Based on a Web-
Based PCR Array Data Analysis protocol provided by
SABiosciences (Qiagen), the absent, low and high ex-
pression levels of chemokines were defined as >35, 30–
35 and <30 average threshold cycles, respectively.
OVCAR-3 cells highly expressed CCL20, CCL28,
CXCL1, CXCL2, CXCL3 and CXCL8. Except for CCL28,
all were responsive to EGF or TNF (Figure 1A and
Table 1). Although control CCL2 and CXCL16 cytokines
were expressed at low levels, they were both highly ele-
vated following the addition of EGF or TNF. The effects
on CCL2, CCL20 and CXCL8 levels appeared to be syn-
ergistic when both EGF and TNF were added (Figure 1A
and Table 1). Although CXCL6, CXCL10 and CX3CL1
were induced by EGF or TNF, overall they had a low ex-
pression (Figure 1A). OVCAR-3 cells displayed absent or
low chemokine receptor levels. Although CXCR4 was re-
sponsive to EGF or TNF, the expression levels post
addition of either factor, were still low (Figure 1B). In
addition, EGF activated Akt and Erk whereas TNF solely
activated IκB in OVCAR-3 cells (Figure 1C).
SKOV-3 cells expressed high levels of CCL26, CCL28,
CXCL1, CXCL8 and CXCL16; of these, CXCL1 and
CXCL8 were responsive to either EGF or TNF (Figure 2A
and Table 1). Although CCL20, CXCL2 and CXCL3
were expressed at low levels in the absence of EGF or
TNF, they were highly expressed by EGF and TNF.
Based on the fact that the level of CCL20 and CXCL8 in
SKOV-3 cells exposed to both EGF and TNF were
greater than the sum of the levels reached with either
EGF or TNF alone, we judged that in these cases, there
was a synergistic effect of EGF and TGF in these cells
(Figure 2A and Table 1). In SKOV-3 cells chemokine re-
ceptor levels were either absent or low and had no re-
sponsiveness to either EGF or TNF (Figure 2B). SKOV-3
cells had a constitutively high level of phosphorylated
(activated) Akt that did not appear to be influenced by
the addition of EGF or TNF. However EGF activated Erk
without IκB phosphorylation whereas TNF highly acti-
vated IκB and had a small effect on the activation of Erk
(Figure 2C).
CaOV-3 cells highly expressed CCL20, CCL25, CCL28,
CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, CXCL14 and
CXCL16, of which CCL20, CXCL2 and CXCL8 were
more responsive to EGF than TNF (Figure 3A and
Table 1). CXCL8 appeared to be synergistically elevated
in the presence of both EGF and TNF (Figure 3A and
Table 1). CaOV-3 cells displayed high basal levels of
Figure 1 EGF- or TNF-responsive chemokine signatures in OVCAR-3 cells. EGF- or TNF-responsive chemokines (A) and chemokine receptors
(B) were determined by PCR array. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 h. Values shown are
fold changes compared to vehicle controls. After isolating total RNA, a real-time PCR was performed using a customized human chemokine PCR
array. The dashed lines in (A) and (B) indicate the equivalent of 2-fold changes from controls. A chemokine signature with a >2-fold increase was
considered to be EGF- or TNF-responsive. White, blue, green and red blocks indicate absent, low, transient (low to high) and high expression
levels of chemokines, respectively, based on a >35, 30–35, 30–35 to <30, and <30, on average, threshold cycle. An asterisk (*) indicates EGF- or
TNF-responsive chemokines with a high expression level (below an average threshold cycle of 30). (C) Effects of EGF or TNF on IκB, Akt and Erk
activation. OVCAR-3 cells were treated with EGF (10 ng/ml) or TNF (10 ng/ml), or both, for 0–60 min. Whole cell lysates were prepared and IκB,
Akt and Erk activations were confirmed by Western blot analyses. Experiments were performed in duplicate and a representative result is shown.
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EGF or TNF. Although CXCR5 level was low, it was
highly expressed in response to EGF or TNF (Figure 3B
and Table 1). EGF activated IκB, Akt and Erk whereas
TNF activated only IκB and reduced EGF-activated Akt
and Erk in these cells (Figure 3C).
Lastly, TOV-21G cells highly expressed CCL2, CCL25,
CCL28, CXCL1, CXCL2, CXCL3, CXCL5, CXCL12,
CXCL14 and CXCL16, of which CXCL1, CXCL2 and
CXCL3 were more responsive to EGF than TNF (Figure 4A
and Table 1). Although baseline TOV-21G cellular CXCL8
values were expressed at low levels, it was highly expressed
by EGF (Figure 4A and Table 1). TOV-21G cells displayed
high levels of CCR10, CXCR4 and CXCR6, which were
unresponsive to EGF or TNF (Figure 4B and Table 1).
Although CXCR5 was responsive to EGF or TNF, its
expression level was still low (Figure 4B and Table 1).
TOV-21G cells had constitutively high Akt activation
levels. EGF activated IκB and Erk whereas TNF activated
only IκB (Figure 4C).
Confirmation of EGF- or TNF-responsive chemokines in
ovarian cancer cells
Based on chemokines and chemokine receptors influenced
by EGF or TNF in PCR array data (Figures 1, 2, 3 and4 and Table 1), we confirmed EGF- or TNF-responsive
chemokines using qRT-PCR with specific chemokine
primers. CCL2, CCL20 and CXCL8 were synergistic-
ally elevated (P ≤ 0.05) in response to EGF and TNF in
OVCAR-3 cells (Figure 5A). On the other hand, CXCL1,
CXCL2 and CXCL3 were more responsive to TNF
compared to EGF while CXCL16 responded similarly
to both EGF and TNF (Figure 5A). Interestingly, although
SKOV-3 cells showed a significant synergistic response
of CCL20, CXCL1, CXCL2, CXCL3 and CXCL8 (P ≤ 0.05)
levels to the addition of EGF plus TNF, TNF alone had
a greater effect than EGF alone (Figure 5B). Induction
levels of CCL20 or CXC8 were larger than those of
CXCL1-3 (Figure 5B).
CaOV-3 cells exposed to EGF plus TNF synergistic-
ally elevated CXCL8 and CXCR5 (P ≤ 0.05), but showed
a dominant effect of EGF>TNF, when each was added
alone (Figure 5C). CCL20 and CXCL2 levels also
underwent a greater increase with EGF added alone,
than TNF (Figure 5C). Finally TOV-21G cells induced
CXCL1-3 and CXCL8 without any apparent synergistic
effect in response to EGF plus TNF. They also showed
a greater induction by EGF than TNF (Figure 5D). The
synergistic responses observed (Figure 5) were consist-
ent with our PCR array data (Table 1).
Table 1 EGF- and/or TNF-responsive chemokines and chemokine receptors obtained in ovarian cancer cell lines
OVCAR-3 SKOV-3 CaOV-3 TOV-21G
Chemokine EGF TNF ET EGF TNF ET EGF TNF ET EGF TNF ET
CCL2 2.95 7.01 12.86 1.28 -1.03 1.38
CCL20 2.20 3.41 7.19 3.68 2.96 23.26 2.66 1.20 3.10
CCL25 1.02 1.37 1.43 1.31 1.39 1.17
CCL26 -1.44 -1.11 1.02
CCL28 1.77 1.55 1.42 -1.06 -1.02 -1.08 -1.09 1.21 1.06 -1.11 1.21 -1.25
CXCL1 2.53 4.38 6.48 2.64 8.03 10.56 1.72 1.59 2.25 3.02 1.07 3.23
CXCL2 3.43 4.99 8.97 1.87 13.98 12.82 5.82 1.83 7.67 4.81 1.04 5.82
CXCL3 2.81 6.73 9.68 1.45 9.09 10.85 1.30 1.55 1.82 2.80 1.25 3.51
CXCL5 1.28 -1.00 1.33
CXCL8 3.73 4.38 11.67 6.19 9.75 35.02 5.74 1.90 9.85 5.15 1.00 5.74
CXCL12 -1.33 1.26 -1.13
CXCL14 -1.24 1.19 -1.04 -1.14 1.23 -1.03
CXCL16 2.40 2.50 2.74 -1.02 1.00 -1.23 1.12 1.33 1.09 -1.04 1.20 -1.09
Receptor
CCR10 -1.36 1.14 -1.25
CXCR4 1.32 1.70 1.62 1.38 1.15 1.27
CXCR5 5.24 3.33 10.63
CXCR6 1.08 1.24 -1.06
CXCR7 -1.10 -1.04 -1.44
Only PCR array data for highly expressed chemokines and chemokine receptors (below an average threshold cycle of 30) are described above. Values shown
represent the fold changes over baseline values, in the presence of EGF, TNF or both (ET). Bold numbers indicate EGF- or TNF-responsive chemokines and
chemokine receptors levels that were elevated > 2-fold among highly expressed chemokines. Bold underlined numbers indicate the presence of a significant
synergism when both EGF and TNF were added.
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EGF- or TNF-activated Akt, Erk and IκB in ovarian
cancer cells
Based on different responses to EGF or TNF in ovarian
cancer cells (Figures 1, 2, 3, 4 and 5), we compared those
signaling components previously related with EGF- or
TNF-activated Akt, Erk and IκB in ovarian cancer
cells. We measured and compared ErbB isoforms, Akt,
the MAPK pathway (Erk, p38 and SAPK/JNK), IKK
isoforms, IκB, and the NF-κB family in nonstimulated
ovarian cancer cells and compared their differential
expression patterns. All cell lines expressed ErbB1, a
specific receptor for EGF; SKOV-3 also highly expressed
ErbB2 (Figure 6A). CaOV-3 cells expressed less Akt
(Figure 6A), indicating less EGF-mediated activation of
Akt (Figure 3C). Erk, p38 and SAPK/JNK expressions
were similar between the cell lines (Figure 6B). Interest-
ingly CaOV3 and TOV-21G cells highly expressed IKKα
whereas OVCAR-3 and SKOV-3 cells highly expressed
IκB (Figure 6C). In addition, CaOV3 and TOV-21G cells
highly expressed p52 as compared to OVCAR-3 and
SKOV-3 cells (Figure 6D). These baseline data support
our findings that OVCAR-3 and SKOV-3 cells are moreresponsive to TNF while CaOV3 and TOV-21G cells
more responsive to EGF.
CCL20 and CXCL8 promoter activities in response to EGF
and TNF in ovarian cancer cells
The regulation of CCL20, CXCL1-3 and CXCL8 is well
known [10]. Our findings indicated that the addition of
EGF plus TNF produced a synergistic effect on the levels
of CCL20 and CXCL8 in OVCAR-3 and SKOV-3 cells
(Figure 5). We therefore generated CCL20 and CXCL8
promoters to determine the effects of EGF and TNF on
the regulation of CCL20 and CXCL8 at the promoter
level. The data show that CCL20 and CXCL8 promoter
activities synergistically responded to EGF plus TNF
(P ≤ 0.05) in OVCAR-3 cells, although when added sep-
arately, TNF had a dominant effect (Figure 7A and 7B).
BAY-11-7082 (NF-κB inhibitor) significantly reduced this
effect on the CCL20 and CXCL8 promoters in contrast
to LY294002 (Akt inhibitor) and PD98059 (Erk inhibitor)
(Figure 7 and 7B).
EGF and TNF synergistically induced CXCL8 pro-
moter activity (P ≤ 0.05) and EGF alone had a greater re-
sponse than TNF alone in CaOV-3 cells (Figure 7B).
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moter activities whereas BAY-11-7082 and PD98059 had
no effect (Figure 7A and 7B). This fact supported that
CaOV-3 cells were more sensitive to EGF > TNF, when
each was given alone (Figure 5C).
Although CCL20 was only produced at low levels
in TOV-21G cells [even in response to EGF and TNF
(Figure 4A)], CCL20 promoter activity responded to
both EGF > TNF when each was given alone (Figure 7A).
BAY-11-7082 and LY294002 had no effect whereas
PD98059 significantly reduced CCL20 promoter activity
(Figure 7A). While TOV-21G cells increased CXCL8
promoter activity in response to EGF or TNF, this effect
was greater in EGF exposed cells (Figure 7B). LY294002
and PD98059 significantly reduced CXCL8 promoter
activity whereas BAY-11-7082 had no effect in these
cells (Figure 7B). TNF-dominant responsive cells such
as OVCAR-3 and SKOV-3 were found to be sensitive
to an NF-κB inhibitor while EGF-dominant responsive
cells such as CaOV-2 and TOV-21G were sensitive to
Akt or Erk inhibitors.Discussion
One of the primary findings in this study is that in these
four ovarian cancer cell lines, CCL20, CXCL1-3 andFigure 2 EGF- or TNF-responsive chemokine signatures in SKOV-3 cel
(B) were determined by PCR array. Cells were incubated with vehicle (Cont
fold changes compared to vehicle controls. After isolating total RNA, a real
array. Dashed lines in (A) and (B) indicate the equivalent of 2-fold changes
considered to be EGF- or TNF-responsive. White, blue, green and red block
levels of chemokines, respectively, based on a >35, 30–35, 30–35 to <30, an
TNF-responsive chemokines with a high expression level (below an averag
activation. Cells were treated with EGF (10 ng/ml) or TNF (10 ng/ml) to bot
activations were confirmed by Western blot analyses. Experiments were peCXCL8 were the major chemokines that responded to
EGF or TNF by involving NF-κB, Akt and Erk signaling
pathways. Particularly, CCL20 and CXCL8 levels were
synergistically elevated in response to a combination of
EGF plus TNF.
Although the chemokine signature profile was to some
degree cell-type specific, the most highly expressed
chemokines were as follows: CCL20, CCL28, CXCL1-3,
CXCL8 and CXCL16. These experimental findings are
supported by clinical data showing that CXCL1 expres-
sion levels are greater in ovarian cancer than in normal
ovary tissues and are also higher in sera from women
with ovarian cancer [18]. CXCL8 has also been shown to
be higher in ascites isolated from ovarian cancer patients
than in ascites of women with benign tumors [19,20].
We found that CCL28 and CXCL16 were either unre-
sponsive or far less responsive to EGF or TNF. Although
CCL28 levels remain unchanged in these ovarian cell
lines, TNF has been shown to increase CCL28 in cul-
tured canine keratinocytes [21] and in A549 human air-
way epithelial-like cells, via NF-κB signaling [22]. These
differences indicate that the chemokine network is likely
to be differentially regulated in various cell types. In case
of CXCL16, only OVCAR-3 cells induced CXCL16 in re-
sponse to EGF or TNF, although the effect was very
small. The effect of TNF on CXCL16 regulation is stillls. EGF- or TNF-responsive chemokines (A) and chemokine receptors
rol), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 h. Values shown are
-time PCR was performed using a customized human chemokine PCR
from controls. A chemokine signature with a >2-fold increase was
s indicate absent, low, transient (low to high) and high expression
d <30, on average, threshold cycle. An asterisk (*) indicates EGF- or
e threshold cycle of 30). (C) Effects of EGF or TNF on IκB, Akt and Erk
h for 0–60 min. Whole cell lysates were prepared and IκB, Akt and Erk
rformed in duplicate and a representative result is shown.
Figure 4 EGF- or TNF-responsive chemokine signatures in TOV-21G cells. EGF- or TNF-responsive chemokines (A) and chemokine receptors
(B) were determined by PCR array. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 hour. Values shown
are fold changes compared to vehicle controls. After isolating total RNA, a real-time PCR was performed using a customized human chemokine
PCR array. Dotted lines indicate the equivalent of 2-fold changes from controls; chemokine signature with a greater than 2-fold increase is
recognized as EGF- or TNF-responsiveness. White, blue, green and red blocks indicate absent, low, transient (low to high) and high expression
levels of chemokines, respectively, based on a >35, 30–35, 30–35 to <30 and <30, on average, threshold cycle. Asterisk indicates EGF- or
TNF-responsive chemokines with a high expression level (below an average threshold cycle of 30). (C) Effects of EGF or TNF on IκB, Akt and Erk
activation. Cells were treated with EGF (10 ng/ml) or TNF (10 ng/ml) for 0 to 60 min. Whole cell lysates were prepared and IκB, Akt and Erk
activations were confirmed by Western blot analyses. Experiments were performed in duplicate and a representative result is shown.
Figure 3 EGF- or TNF-responsive chemokine signatures in CaOV-3 cells. EGF- or TNF-responsive chemokines (A) and chemokine receptors
(B) were determined by PCR array. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or both for 1 h. Values shown are
fold changes compared to vehicle controls. After isolating total RNA, a real-time PCR was performed using a customized human chemokine PCR
array. Dashed lines indicate the equivalent of 2-fold changes from controls. A chemokine signature with a >2-fold increase was considered as
EGF- or TNF-responsive. White, blue, green and red blocks indicate an absent, low, transient (low to high) and high expression level of
chemokines, respectively, based on a >35, 30–35, 30–35 to <30 and <30, on average, threshold cycle. An asterisk (*) indicates EGF- or
TNF-responsive chemokines with a high expression level (below an average threshold cycle of 30). (C) Effects of EGF or TNF (or both) on IκB, Akt
and Erk activation. Cells were treated with EGF (10 ng/ml) or TNF (10 ng/ml) for 0–60 min. Whole cell lysates were prepared and IκB, Akt and Erk
activations were confirmed by Western blot analyses. Experiments were performed in duplicate and a representative result is shown.
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Figure 5 Confirmation of EGF- or TNF-responsive chemokines in ovarian cancer cell lines. (A) Effects of EGF or TNF on CCL2, CCL20,
CXCL1, CXCL2, CXCL3, CXCL8 and CXCL16 by qRT-PCR in OVCAR-3 cells. (B) Effects of EGF or TNF on CCL20, CXCL1, CXCL2, CXCL3 and CXCL8 by
qRT-PCR in SKOV-3 cells. (C) Effects of EGF or TNF on CCL20, CXCL2, CXCL8 and CXCR5 by qRT-PCR in CaOV-3 cells. (D) Effects of EGF or TNF on
CXCL1, CXCL2, CXCL3 and CXCL8 by qRT-PCR in TOV-21G cells. Cells were incubated with vehicle (Control), EGF (10 ng/ml), TNF (10 ng/ml) or
both for 1 h. After isolating total RNA, a qRT-PCR array was performed using specific chemokine primers. An asterisk (*) indicates a significant
synergistic effect of the combination of EGF and TNF on chemokine expression (P ≤ 0.05) within each group as monitored by ANOVA and Tukey’s
pairwise comparisons. Experiments were performed in triplicate and all data are shown as mean ± SEM.
Figure 6 The baseline expression of signaling components associated with EGF- or TNF-activation. Expression levels of ErbB isoforms and
Akt (A), MAPK pathway (B), IKK isoforms and IκB (C), and NF-κB family (D) in OVCAR-3 (OV), SKOV-3 (SK), CaOV3 (Ca) and TOV-21G (TOV) cells.
Whole cell lysates were prepared and protein expression levels were confirmed by Western blot analyses. Experiments were performed in
duplicate and a representative result is shown.
Son et al. Journal of Inflammation 2013, 10:25 Page 8 of 12
http://www.journal-inflammation.com/content/10/1/25
Son et al. Journal of Inflammation 2013, 10:25 Page 9 of 12
http://www.journal-inflammation.com/content/10/1/25controversial in other model systems. TNF increased
CXCL16 in human gingival fibroblasts [23] whereas it
had no effect in human vascular smooth muscle cells
[24] or in human bronchial epithelial cells [25]. CXCL16
contains a functional activator protein-1 (AP-1) binding
motif, and PI3K inhibitors and a c-Jun N-terminal kinase
(JNK) inhibitor attenuated IL-18-mediated AP-1 binding
and CXCL16 promoter-reporter activity [26]. These facts
suggest that EGF or TNF may increase CXCL16 via
PI3K or JNK activation, respectively, in OVCAR-3 cells.
On the other hand, CCL20, CXCL1-3 and CXCL8
were highly responsive to EGF or TNF. Because these
chemokines contain κB sites on their promoters [13],
NF-κB signaling is likely to play a primary role as a
regulator. Because EGF does not directly activate NF-
κB signaling in OVCAR-3 and SKOV-3 cells, a TNF-
activated NF-κB pathway appears to be more dominant
in these cells compared to EGF mediated pathways.
Interestingly, EGFR-activated NF-κB was observed inFigure 7 Promoter activities for EGF- or TNF-responsive CCL20 and C
promoter activity (B) in response to EGF (E), TNF (T) or both (ET) ± inhibitor
(PD98059, PD 10 μM) in OVCAR-3, SKOV-3, CaOV3 and TOV-21G cells. After
luciferase assay was performed. Results were normalized to total protein co
Different asterisks (*,**,***) indicate significantly increased differences (P≤ 0
number sign (#) indicates a significant decrease (P ≤ 0.05) compared to EGF
Student’s t-test. Experiments were performed in triplicate and all data are sboth CaOV-3 and TOV-21G cells, explaining the dom-
inant responsiveness of EGF in these lines. In addition,
these cells had high levels of IKKα and p52 and low
levels of IκB, supporting the concept that a non-
canonical NF-κB pathway was involved in their low re-
sponse to TNF. On the other hand, OVCAR-3 and
SKOV-3 cells had low levels of IKKα and p52 and high
levels of IκB, supporting a canonical NF-κB pathway
responsible for their dominant response to TNF.
Actually the relationship between EGFR activation
and NF-κB signaling is very controversial in other
model systems. For instance, heparin-binding EGF-like
growth factor (HB-EGF) inhibited NF-κB activation via
PI3K-dependent phosphorylation of Akt in cytokine-
stimulated intestinal epithelial cells [27]. In contrast,
EGF contributed to NF-κB activity in human proximal
tubule cells [28] and in pancreatic cancer [29]. In
addition, EGF did not activate NF-κB or alter NF-κB
activation by TNF in chondrocytes [30]. Despite eitherXCL8 in ovarian cancer cells. CCL20 promoter activity (A) and CXCL8
s for IκB (BAY-11-7082, Bay 2 μM), Akt (LY294002, LY 2 μM) and Erk
transfection with CCL20 and CXCL8 luciferase vectors overnight, a
ncentrations and expressed as fold increases compared to controls.
.05) within each group by ANOVA and Tukey’s pairwise comparison. A
and TNF (ET) measures in the absence of inhibitors, as calculated by
hown as mean ± SEM.
Figure 8 Schematic proposal of EGF- or TNF-responsive
chemokines in ovarian cancer cells. EGFR, frequently
overexpressed in high-grade ovarian cancer, activates Akt and Erk in
response to EGF, resulting to secretion of proinflammatory
chemokines such as CCL20, CXCL1-3, and CXCL8, all of which
contain κB sites in their promoters. Also TNF, a proinflammatory
cytokine abundantly expressed in ovarian cancer, induces NF-κB
activation followed by secretion of proinflammatory chemokines.
Although the response to TNF or EGF is cell-type specific, ovarian
cancer cells mainly induce proinflammatory chemokines such as
CCL20, CXCL1-3, and CXCL8 through additive or synergistic
interaction between EGF and TNF. The enhanced chemokines
reinforce the proinflammatory tumor microenvironment for ovarian
cancer progression such as peritoneal tumor dissemination and the
production of massive ascites which promote the higher mortality
rates seen with this malignancy.
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induce CCL20, CXCL1-3 and CXCL8 through Akt/Erk
activation in ovarian cancer cells. In support of this,
EGF was found to activate NF-κB and induce CXCL1
in murine squamous cell carcinoma [31]. The fact that
an EGF-induced increase in CXCL1 and CXCL8 was
decreased by MAPK inhibitors in ovarian cancer cells
[16] indicates involvement of Akt or Erk signaling.
In particular, EGF synergistically induced CCL20 and
CXCL8 by cooperating with TNF. CXCL8 is well known
to be regulated by NF-κB signaling [32]. In addition to
NF-κB signaling, TNF-upregulated CXCL8 is likely to in-
volve JNK and the p38 MAPK pathway [33]. EGF has also
been found to induce the release of CXCL8 through signal-
ing pathways involving Erk and PI3K in MCF-7 breast
carcinoma cells [34]. In addition, EGFR/Erk and AP-1 path-
ways were found to be involved in MMP12-induced
CXCL8 release from the alveolar epithelium [35]. Thus the
combination of EGF and TNF in these studies seems to
have boosted CXCL8 expression by coordinating NF-κB,
Akt and Erk signaling pathways.
Also CCL20 expression is under the direct control of
NF-κB in mouse liver [36] and TNF upregulates CCL20
via NF-κB signaling in intestinal epithelial-type cells [37].
The NF-κB site in CCL20 promoter is critical for LDL
responsiveness [38]. In addition to NF-κB signaling, the
CCAAT/enhancer binding protein β (C/EBPβ) is a criticalregulator of CCL20 in normal human keratinocytes [39].
Proinflammatory cytokine IL-6 stimulates CCL20 expres-
sion in part through STAT3 activation in primary murine
astrocytes [40]. The miR-21 functionally interacts with
the 3′UTR of CCL20 mRNA in colorectal cancer cells,
resulting in downregulation of CCL20 [41]. IL-17F is able
to induce CCL20 via Erk signaling in bronchial epithelial
cells [42]. Similarly with TNF, the combination of IL-1 and
EGFR ligands synergistically provoked CCL20 in human
keratinocytes [43]. Various signaling pathways involved in
CCL20 regulation supports the synergistic effects of EGF
and TNF on CCL20 expression by collaboratively involving
the NF-κB, Akt and Erk signaling pathways.
Thus TNF-dominant responsive cells (OVCAR-3 and
SKOV-3) produced a greater synergistic effect on CCL20
and CXCL8 mRNA when compared to EGF-dominant
responsive cells (CaOV-2 and TOV-21G cells). This may
be due to the fact that CCL20 and CXCL8 promoters
contain a κB site as a main responsive element [10].
Furthermore, promoter assays for CCL20 and CXCL8
supported the synergistic effects of EGF and TNF on
CCL20 and CXCL8 via collaboration between the NF-κB
and Akt/Erk signaling pathways.
Compared to chemokines, it was difficult to find cell-type
specific patterns for chemokine receptors in these cell lines.
OVCAR-3 and SKOV-3 cells had either no, or a very low
expression of chemokine receptors. Also those ovarian can-
cer cells with a high endogenous expression of TNF,
expressed higher levels of CXCR4 than cells with a low
TNF expression [11]. Despite a low expression, however,
CXCR4 was responsive to EGF or TNF in OVCAR-3 cells.
Although a 24 h treatment with EGF enhanced CXCR4
through PI3K/Akt signaling in SKOV-3 cells [17], the basal
level of CXCR4 was found to be low in these cells. Further,
even though CaOV-3 and TOV-21G cells expressed high
levels of CXCR4, EGF or TNF had no effect on CXCR4 ex-
pression in these cell lines. The low response to TNF in
CaOV-3 and TOV-21G cells is likely due to their poor
responsiveness of CXCR4 expression. Because TOV-21G
cells highly express CXCL12/CXCR4 and CXCL16/CXCR6
axes in spite of a low response to EGF or TNF, these axes
may contribute to cancer progression as described by
others [44,45].
Interestingly, CXCR5 was responsive to EGF or TNF
in CaOV-3 and TOV-21G cells. Although CXCR5 pro-
motes the growth of tumor cells in the liver [46], the
role(s) of CXCR5 in ovarian cancer is poorly under-
stood. As the cancer cells tested do not express CXCL13
(a ligand for CXCR5), the novel role of CXCR5 in ovar-
ian cancer cells in response to EGF or TNF may high-
light their interaction with immune cells expressing
CXCL13 in the tumor microenvironment. Because
inflammation-driven ovarian cancer was found to en-
hance CXCL1-3 expression [10], - targeting CXCR2, a
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strategy as suggested by others [47]. Based on the syner-
gistic increase of CCL20 and CXCL8 in response to EGF
and TNF, CCL20 and CXCL8 may be the dominant
chemokines found in ovarian cancer cells with abundant
TNF, and/or activation of the EGFR. CXCL8 reportedly
may function as an important therapeutic target in colo-
rectal cancers [48]. A high expression of CXCL8 was
found to be a poor prognostic factor of urothelial blad-
der cancer [49]. Increased expression levels of CXCL8
may also contribute to the multidrug resistance seen in
human breast cancer cells [50]. High expression of
CCL20 is also closely associated with poor clinical out-
come of patients with gliomas [51] and with a poorer
prognosis in patients with hepatocellular carcinoma
[52]. The CCL20/CCR6 axis has been shown to promote
non-small cell lung cancer progression [53]. Also CCL20 is
up-regulated in pancreatic cancer [54] and overexpression
of CCL20 in prostate cancer cells promotes tumor growth
and invasiveness [55]. Based on these critical roles of
CXCL8 and CCL20, high-grade ovarian cancer cells with
abundant TNF and EGFR activation may augment these
proinflammatory chemokines to provide an inflammatory
tumor microenvironment promoting cancer progression
and leading to poorer outcomes and an increase in cancer
deaths (Figure 8).
Conclusion
Our results indicate that ovarian cancer cells induce CCL20,
CXCL1-3 and CXCL8 as the primary chemokines in re-
sponse to EGF or TNF. Further, CCL20 and CXCL8 can be
significantly elevated by the synergistic actions of EGF
plus TNF. Targeting these proinflammatory chemokines
may support a promising therapeutic strategy for inflam-
matory ovarian cancer with abundant TNF and EGFR
activation pathways.
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